PL
Therapeutic Areas
Royalty Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Imbruvica | Oncology (CLL, MCL) | Marketed |
| Xtandi | Prostate Cancer | Marketed |
| Tysabri | Multiple Sclerosis | Marketed |
| Gilead HIV Franchise | HIV | Marketed |
| Trikafta/Kaftrio | Cystic Fibrosis | Marketed |
| JNJ-4804 | Autoimmune Diseases | Development |
| Cabometyx | Renal Cell Carcinoma, Hepatocellular Carcinoma | Marketed |
| Evrenzo (Roxadustat) | Anemia in Chronic Kidney Disease | Marketed (ex-US) |
Leadership Team at Royalty Pharma
TC
Terrance Coyne
Chief Financial Officer
CH
Christopher Hite
Chairman, Partnering & Investments
MU
Marshall Urist
Head of Research & Investments
GL
George Lloyd
Senior Advisor
LG
Lucas Glass
Head of Artificial Intelligence (effective April 2026)
GB
Greg Butz
Executive Vice President, Partnering & Investments (effective June 2026)
KS
Kenneth Sun
Senior Vice President and Head of Asia (effective May 2026)